Should FDA Rules Preempt State Abortion Pill Restrictions?

The Supremacy Clause called; it wants its job back. FDA approval isn’t a Yelp review—it’s a national scientific determination designed to create one uniform standard for drug safety and access. Mifepristone has two decades of robust data, a REMS program the FDA updated in 2023 to allow certified pharmacies and telehealth, and a recent Supreme Court term (AHM v. FDA, June 2024) that left those judgments intact by tossing the challenge for lack of standing. States trying to veto that with “because we feel like it” laws aren’t doing federalism; they’re doing science-by-zip-code. Wyeth v. Levine didn’t give states a veto over federal drug policy—if state rules stand as an obstacle to FDA’s expert risk–benefit balancing, preemption isn’t a dirty word; it’s Constitutional housekeeping. We already let medical device approvals preempt conflicting state rules (Riegel), because uniformity matters when lives are on the line. If pharmacists in Ohio, doctors in New York, and patients in Arizona need three different rulebooks to dispense the same FDA-approved medication, that’s not safety; that’s chaos dressed as local control. And please, let’s not resurrect the Comstock Act like a Victorian prop from the attic to micromanage 21st-century telemedicine—DOJ has already clarified its limits, and Congress hasn’t said, ‘turn back the clock.’ The FDA’s remit is science and safety; states don’t get to nullify federal approvals because the politics got spicy. If you want nationwide consistency, you need federal supremacy. Otherwise, we’re just letting ideology be the pharmacist.

Dobbs wasn’t a Hallmark card; it was a constitutional handoff, returning abortion policy to the states where the police power lives. The Food, Drug, and Cosmetic Act contains no express preemption for abortion policy, and Wyeth v. Levine is a neon sign that states can be stricter than FDA about risks—especially when the subject isn’t just pharmacology but the protection of unborn life and maternal health. If Washington wants to nationalize abortion via the pill, Congress can pass a law; until then, the FDA doesn’t get to convert a drug label into a nationwide moral settlement. Let’s not pretend the FDA is infallible or apolitical—its 2016 and 2021 changes and the 2023 telehealth dispensing shift were, at minimum, contested, with real concerns about in-person exams for ectopic pregnancy and the ability to monitor complications. Different states weigh those risks and values differently; that’s called federalism, not heresy. The Supreme Court’s 2024 decision in the mifepristone case dodged the merits on standing, so the door is wide open for state regulation. Uniformity sounds tidy until it bulldozes community standards and the basic constitutional architecture. Patchwork is not a bug—it’s the design of laboratories of democracy. If California wants looser rules and Texas wants tighter ones, that’s the system working. FDA approval means a drug may be marketed; it does not mean every state must allow every use in every circumstance—and it certainly doesn’t turn an agency into the nation’s abortion czar.

Dobbs was a handoff on abortion policy, not a permission slip to toss the Food, Drug, and Cosmetic Act in the shredder. We’ve been here before: when Massachusetts tried to block an FDA‑approved opioid (Zogenix v. Patrick), a federal court said, nice try—states can’t embargo an approved drug because they disagree with the agency’s risk calculus. Swap painkiller for mifepristone and the principle doesn’t change just because the politics got louder. The FDCA builds a national market for approved drugs; states don’t get to put a ‘closed for ideology’ sign on the pharmacy window. And spare me the “practice of medicine” fig leaf. 21 U.S.C. § 396 keeps FDA from micromanaging doctors, yes, but it doesn’t license states to torpedo access by overriding the agency’s distribution scheme. When the FDA crafts a REMS that expressly allows certified pharmacies and telehealth dispensing, a state rule that demands in‑person pickup or bans mail pharmacy isn’t harmless ‘extra caution’—it’s a direct collision. Obstacle preemption still exists (see Geier), and Buckman warned against states freelancing as mini‑FDAs. You can regulate bedside manners; you can’t relitigate the label. If we’re invoking grand doctrines, try this one on for size: the Major Questions Doctrine cuts both ways. Turning the FDCA into a 50‑state veto machine would itself demand a clear statement from Congress—yet Congress set up a national approval regime, not a moral exception menu. We don’t let states ban insulin‑by‑mail because they dislike needles, and we shouldn’t let them ban mifepristone‑by‑mail because they dislike the outcome. The Commerce Clause didn’t retire just because someone discovered Zoom. The patchwork isn’t theoretical—it’s patients whipsawed by borders, ERs triaging law before medicine, and the Idaho EMTALA saga previewing chaos when health care gets Balkanized. Federal supremacy here isn’t a victory lap for Washington; it’s a basic operating manual for a country where people move, mail moves, and medicine shouldn’t be a choose‑your‑own‑adventure depending on the highway exit.

The Supremacy Clause isn’t a magic wand and an FDA label isn’t a national moral settlement. Dobbs returned abortion to the states—where police powers live—and nothing in the FDCA turns the agency into the nation’s abortion commissioner. Approval means a drug may be marketed; it does not mean every state must allow every use in every circumstance. If Congress wants a nationwide abortion‑pill regime, Congress can say so—in actual words, not in the white space of a package insert. Start with the text Congress did write: 21 U.S.C. § 396. The FDA doesn’t regulate the practice of medicine; states do—licensure, telehealth rules, in‑person exams, standards of care, protection of minors. A REMS is a floor for manufacturers, not a ceiling on state health and safety judgments. Zogenix? That was an outright, emergency ban on a drug across the board. Here, many states are regulating a procedure (abortion) and the conditions under which their doctors may use a particular drug for that procedure. They are not second‑guessing the molecule; they are setting the bounds of medical practice and protecting mothers and unborn life—the heartland of state authority. And if we’re trading doctrines, try the Major Questions and clear‑statement rules. Using the FDCA to preempt state abortion policy—an issue of profound moral and social consequence—flunks West Virginia v. EPA and Gregory v. Ashcroft. You don’t erase state police powers with implications that happen to be convenient to federal agencies. No unmistakably clear text, no nationwide preemption. Practical reality only reinforces the point. Cross‑border telehealth, shield laws, and pharmacies shipping pills create enforcement headaches and real risks—especially for minors and for detecting contraindications like ectopic pregnancy. States have every right to require in‑person exams, limit telehealth, and police the mail coming into their borders. And the Comstock Act hasn’t been repealed; an OLC memo isn’t a judicial permission slip. Patchwork isn’t a bug; it’s the laboratories of democracy doing QA on a life‑and‑death question. If uniformity is the goal, the proper tool is legislation—not agency alchemy.

New rule of the road: “states’ rights” doesn’t mean a state DMV gets to rewrite the drug label. Congress built REMS to be a single national playbook, with FDA deciding the Elements To Assure Safe Use under 21 U.S.C. § 355‑1. That’s not a DIY kit for 50 moral add‑ons. The whole point of a “single, shared system” is that patients and prescribers aren’t hopscotching between contradictory hoops—telehealth allowed here, forbidden there; certified pharmacies okay here, felonies there. If manufacturers and pharmacies must run one uniform REMS, a state’s in‑person‑only rule or mail ban doesn’t ‘supplement’ the system—it fractures it. And about the mail: states don’t get to stick orange traffic cones in front of the U.S. Postal Service. You can regulate practice within your borders; you can’t commandeer federal channels or criminalize compliance with a federal distribution scheme because your legislature had a 19th‑century flashback. The Comstock cosplay still hasn’t produced a conviction in a century, and OLC’s 2022 opinion set its contemporary limits; treating a zombie statute as a veto on modern telemedicine is less ‘rule of law’ and more ‘LARPing with subpoenas.’ Meanwhile, real hospitals are reporting delayed miscarriage care and pharmacy refusals for perfectly lawful indications—collateral damage from culture‑war crossfire. Post‑Chevron (hello, Loper Bright), we’re back to statutory text and structure, which cut in favor of national uniformity. Congress centralized safety and distribution judgments at FDA so the benefits outweigh risks on a national basis—not so every statehouse can run a parallel mini‑FDA with moral riders attached. When a drug with a two‑decade safety record and a REMS tailored for certified pharmacies and telehealth collides with a patchwork of ideological embargoes, that’s not federalism—it’s sabotage of a congressionally designed market. If you want to change the national rule, bring votes to Congress; until then, stop turning the pharmacy counter into a border checkpoint.

Post‑Chevron reality check: after Loper Bright, “because FDA says so” is not a legal theory. If you’re going to vaporize state police powers on an issue as morally freighted as abortion, you need an unmistakably clear statute—not a REMS footnote. Section 355‑1 coordinates manufacturers and pharmacies; it does not hand HHS a red pen to strike out state standards of medical practice. The “single, shared system” binds companies, not legislatures, and it’s a floor. States still license doctors, set telehealth limits, require in‑person exams, protect minors, and define standard of care. If you can’t draw blood or prescribe Adderall in a dorm room via Zoom, you can bet a state can say the same about a two‑drug abortion regimen. This isn’t an embargo on a molecule; it’s the regulation of a procedure. Many state laws allow non‑abortion indications, regulate gestational limits, mandate ultrasound to date pregnancy, or require follow‑up care—hardly “science by zip code,” more like medicine with a malpractice lawyer’s eye on real‑world risk. FDA narrowed adverse‑event reporting in 2016 and relaxed safeguards in 2021/2023; states looked at the same landscape—ectopic pregnancy detection, coercion, minors—and chose tighter rules. That’s the laboratories of democracy doing their job, not apostasy. And the commerce‑panic doesn’t bail you out. National Pork Producers already told us the Dormant Commerce Clause won’t federalize every moral dispute with spillover effects. States can regulate receipt and use within their borders even if the USPS is the delivery truck; the Postal Clause isn’t a hall pass for anything with a stamp. The Comstock Act is still on the books—no, an OLC memo doesn’t repeal it—and a future DOJ could read it quite differently. Shield laws, cross‑border telehealth, and mail‑order pills have created exactly the enforcement chaos Dobbs anticipated Congress would fix if it wanted uniformity. Until Congress actually writes that uniformity down, patchwork isn’t a bug—it’s the Constitution running quality assurance on policy that quite literally deals in life and death.

If Congress wanted 50 versions of a REMS, it would’ve called it “Choose Your Own Adventure,” not “single, shared system.” Courts already treat FDA’s calibrated risk–benefit judgments as something more than suggestions in the margins. See PLIVA v. Mensing and Mutual Pharm v. Bartlett: when uniformity is the point, states don’t get to bolt on bespoke warning labels because they woke up feeling extra paternal. Merck v. Albrecht puts the judge in the preemption driver’s seat, but it didn’t erase the core idea: where the federal regime is deliberately uniform, state add‑ons that blow up that uniformity are out of bounds. You don’t order a networked thermostat and let every room rewrite its own firmware. And spare me the “but devices had express preemption” gotcha. That proves Congress knows how to demand uniformity when lives and markets need it—and the rest of the FDCA still supports implied preemption when a state plows straight into a federal design. Hillsborough County didn’t abolish obstacle preemption; it asked whether the agency meant to occupy the field. Here, the FDA did more than whisper: it built a nationwide REMS and explicitly green‑lit certified pharmacies and telehealth to match the safety data. Turning that into 50 in‑person pickup mandates is not “prudence”; it’s an obstacle course. Even post‑Loper Bright, text and structure matter—and § 355‑1 tasks FDA with ETASU “commensurate with risk,” not “commensurate with whichever state legislature had a late‑night session.” Federalism isn’t a permission slip for chaos cosplay. The current patchwork has doctors lawyering before prescribing, pharmacies slow‑walking refills for miscarriage management because they fear felony roulette, and patients taking Greyhound tours of neighboring states while ACOG and WHO wave a giant “telemedicine is safe” flag. You can’t celebrate Gonzales v. Raich’s federal interest in a uniform drug market when it bans marijuana and then shrug at balkanization when FDA authorizes a lawful one. Preemption here isn’t agency hubris; it’s how you keep a national drug supply from turning into a border‑patrolled scavenger hunt.

Congress wrote an express preemption clause for devices (21 U.S.C. § 360k) and very conspicuously didn’t for drugs. That’s not a drafting typo; that’s a boundary line. Wyeth and Merck v. Albrecht let state tort law and safety judgments coexist with FDA approvals, and Hillsborough County reminds us health and safety start with a presumption against preemption absent clear congressional intent. If Washington wants to nationalize abortion via a pill, it can say so in text; what it can’t do is smuggle a culture‑wide settlement through a REMS appendix. Gonzales v. Oregon is the second verse: when the feds tried to redefine medical practice without an unmistakable mandate, they lost. The FDCA is even less of a nationwide practice code. Raich doesn’t rescue you; it’s about a federal ban overpowering state permission, not federal permission nullifying state bans. Turning “may be marketed” into “must be available on telehealth and by mail in every state” flunks the Major Questions/clear‑statement test and Gregory v. Ashcroft’s respect for core state functions. Section 396 keeps the FDA out of the practice of medicine for a reason—states set in‑person exam rules, parental involvement, and standards of care. Judges, not agencies, decide preemption after Albrecht; Skidmore gives FDA a polite nod, not a scepter. A REMS can bind manufacturers and pharmacies; it doesn’t bulldoze a state’s medical licensing and patient‑protection regime. On the ground, this isn’t Victorian cosplay; it’s governance. Cross‑border telehealth raises age verification, coercion, and follow‑up care problems that don’t vanish in a Zoom waiting room. States respond with ultrasound dating, in‑person exams, gestational limits, and reporting—tools tailored to risks they bear when complications hit local ERs. National Pork Producers already told us moral spillovers don’t trigger a Dormant Commerce Clause panic. And until Congress actually repeals or replaces the Comstock Act—and clarifies what can move in the mail—it’s hardly irrational for states to align their rules with potential federal enforcement whiplash. If the country wants uniformity, the venue is Article I, not the fine print on a box in aisle 12.

New exhibit, your honors of the statehouse: the Drug Supply Chain Security Act. Congress didn’t build a national track‑and‑trace barcode system so that half the country could slap a “no shipping allowed” sticker on FDA‑approved meds they dislike. DSCSA preempts state-by-state pedigree rules precisely to keep a single, interoperable distribution network. When the FDA’s REMS certifies pharmacies—including for mail fulfillment—and DSCSA creates one supply chain, a state mail embargo isn’t “local flavor,” it’s a wrench in the conveyor belt. You can’t run a national pharmacy network where a bottle is legal on the loading dock in Illinois and a felony at the mailbox in Louisiana. And we already have a proof-of-concept for federal primacy in medicine when the feds are acting in their lane. The VA’s 2022–2024 rule on abortion care for veterans preempts contrary state bans inside federal facilities, and EMTALA litigation has forced states to step back when federal emergency standards require stabilizing care. Translation: when Congress gives an agency a mandate tied to nationwide health operations, state vetoes yield. FDA’s mandate is national drug safety and distribution; pretending that mandate evaporates the second the pill is used for abortion is like saying air traffic control stops at the state line. Meanwhile, the interstate trench warfare—shield laws, bounty statutes, sheriffs with subpoenas chasing UPS tracking numbers—screams for uniformity. Red states are asserting extraterritorial claims over blue‑state prescribers; blue states are responding with jurisdictional force fields. One clean conflict rule solves a lot of nonsense: where FDA has set the safety-and-access architecture for a drug, states don’t get to detonate it for a disfavored indication. And please stop waving the Comstock zombie around; if anyone revives that relic, it will be federal authorities in federal court, not a county DA trying to moonlight as Postmaster General. Post‑Loper Bright, preemption rides on text and structure—not vibes. Section 355‑1 literally assigns FDA the job of crafting the “elements to assure safe use” and building the single, shared system those elements require. DSCSA keeps the distribution rails uniform. When a state injects bespoke hurdles that balkanize those rails—no mail, no telehealth, in‑person pickup only—it collides with the federal design. If you want to outlaw the federal design for mifepristone, do it the grown‑up way: get Congress to change the statute. Until then, stop turning the pharmacy counter into a constitutional escape room.

Let’s not confuse barcodes with bioethics. DSCSA is about track‑and‑trace—safety seals and serial numbers—not about forcing every state to accept every indication by mail. Congress wrote an express preemption for pedigree paperwork and, in the same breath, preserved state licensing and traditional police powers over dispensing and practice. A scannable label doesn’t become a moral permission slip because it beeps. If a state says, “in‑person exam first,” or “no telehealth abortions,” that’s classic medical regulation. DSCSA keeps the supply chain honest; it doesn’t conscript states into the FDA’s latest distribution preferences. Your VA and EMTALA trophies prove my point, not yours. The VA rule applies inside a federal system to federal employees and patients—its own jurisdictional island. EMTALA speaks to emergency stabilization in hospitals that take Medicare funds. Both rest on clear statutory hooks with Congress’s fingerprints all over them. If Congress wanted FDA approval to preempt state abortion limits outside federal enclaves and emergent care, it could say so—clean, loud, unmistakable. It hasn’t. Trying to smuggle nationwide abortion access through a REMS bullet and DSCSA barcodes is the administrative state’s version of “trust me, bro.” As for the interstate food fight, welcome to federalism in action. Shield laws meet public‑policy exceptions, and courts sort out who can hale whom into which forum—like they do in countless choice‑of‑law disputes. That messy sorting is a feature of a Constitution that leaves life‑and‑death police powers close to the people. And beware the tool you’re forging: if FDA can bulldoze state limits today by declaring a distribution pattern, a future administration can reverse course or rewrite labels to impose nationwide restrictions—no votes required. On questions this profound, the answer isn’t agency alchemy or judicial vibes; it’s Congress. Until then, states can demand ultrasounds, mandate in‑person exams, limit telehealth, and set the bounds of a procedure they—not the FDA—must police when complications land in their ERs.